Merck, which previously predicted 2024 sales between 20.7 billion ... continues to regain ground from a slump after the end ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

After-tax profit was 812 million euros compared with 740 million in the same period last year, Merck said Thursday. The ...

Merck, which previously predicted 2024 sales of between 20. ... valuable Life Sciences service that brings together a daily ...

Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...